Costanzo Alessandro, Sandri Andrea, Regis Dario, Trivellin Giacomo, Pierantoni Silvia, Samaila Elena, Magnan Bruno
.
Acta Biomed. 2017 Oct 18;88(4S):31-37. doi: 10.23750/abm.v88i4-S.6791.
Radiofrequency ablation (RFA) is the gold standard for the treatment of symptomatic osteoid osteoma (OO) as RFA yields both a high success and low complication rate. It has been widely utilized over the years, but recurrences of OO after this treatment have been documented. These recurrences may be the result of various factors, including incomplete tumor ablation, and are significantly higher in lesions greater than 10 mm. Thus, the need to induce thermal ablation in a wider area led us to use a Multi-Tined Expandable Electrode System (MTEES). In this study we examined the efficacy and safety of RFA using a MTEES in symptomatic OO.
Between January 2005 and June 2007, 16 patients with symptomatic OO were treated by CT-guided percutaneous RFA using a MTEES. The diameter of OO ranged from 6 to 15 mm (mean 10±2.6 mm). Patients were evaluated for clinical outcomes, complications and recurrence. Pain evaluation was assessed preoperatively, 2 weeks postoperatively and at last follow-up.
Clinical follow-up was available for all patients at a mean of 84.3 months (range 73-96 months). Mean preoperative VAS score was 7.4 (range 5-9), two weeks after the procedure mean VAS score was 0.3 (range 0-1) with a mean change of -7.06 points (p<0.0001). At the last follow-up a complete relief from pain has been observed in all patients. No major and minor complications were observed nor recurrences.
RFA using a MTEES has been effective, safe and reliable for the treatment of OOs. This system, by increasing the size of the necrosis, could be a viable alternative to the single needle electrode in lesions larger than 10 mm, reducing the risk of recurrence.
射频消融(RFA)是治疗有症状骨样骨瘤(OO)的金标准,因为RFA成功率高且并发症发生率低。多年来它已被广泛应用,但该治疗后骨样骨瘤复发的情况已有记录。这些复发可能是多种因素导致的,包括肿瘤消融不完全,且在直径大于10毫米的病灶中复发率显著更高。因此,需要在更广泛区域进行热消融促使我们使用多爪可扩张电极系统(MTEES)。在本研究中,我们检验了使用MTEES进行RFA治疗有症状骨样骨瘤的疗效与安全性。
2005年1月至2007年6月期间,16例有症状骨样骨瘤患者接受了使用MTEES的CT引导下经皮RFA治疗。骨样骨瘤直径为6至15毫米(平均10±2.6毫米)。对患者的临床结果、并发症及复发情况进行评估。术前、术后2周及末次随访时评估疼痛情况。
所有患者均获得临床随访,平均随访时间为84.3个月(范围73 - 96个月)。术前平均视觉模拟评分(VAS)为7.4(范围5 - 9),术后2周平均VAS评分为0.3(范围0 - 1),平均变化为 - 7.06分(p<0.0001)。在末次随访时,所有患者疼痛均完全缓解。未观察到任何严重及轻微并发症,也未出现复发。
使用MTEES进行RFA治疗骨样骨瘤有效、安全且可靠。该系统通过增大坏死范围,对于直径大于10毫米的病灶而言,可能是单针电极的可行替代方案,可降低复发风险。